ANTIPODES PARTNERS Ltd Grows Holdings in Certara, Inc. (NASDAQ:CERT)

ANTIPODES PARTNERS Ltd grew its stake in Certara, Inc. (NASDAQ:CERT) by 204.7% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 5,442 shares of the company’s stock after buying an additional 3,656 shares during the quarter. ANTIPODES PARTNERS Ltd’s holdings in Certara were worth $58,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Venturi Wealth Management LLC boosted its stake in shares of Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company’s stock valued at $30,000 after purchasing an additional 2,509 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of Certara by 20.9% in the 4th quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after purchasing an additional 822 shares in the last quarter. KBC Group NV boosted its stake in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock valued at $57,000 after purchasing an additional 1,584 shares in the last quarter. GAMMA Investing LLC boosted its stake in shares of Certara by 442.2% in the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company’s stock valued at $90,000 after purchasing an additional 6,868 shares in the last quarter. Finally, Moloney Securities Asset Management LLC purchased a new stake in shares of Certara in the 4th quarter valued at $128,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Trading Up 1.0 %

Shares of CERT opened at $11.01 on Thursday. The stock has a market capitalization of $1.77 billion, a P/E ratio of -55.05, a PEG ratio of 9.29 and a beta of 1.60. The company has a quick ratio of 2.86, a current ratio of 2.86 and a debt-to-equity ratio of 0.28. The firm has a fifty day simple moving average of $12.59 and a two-hundred day simple moving average of $11.57. Certara, Inc. has a twelve month low of $9.41 and a twelve month high of $19.29.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. TD Cowen assumed coverage on shares of Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective for the company. Barclays upped their price objective on shares of Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research note on Friday, February 28th. William Blair reaffirmed a “market perform” rating on shares of Certara in a research note on Thursday, February 27th. Finally, Stephens reaffirmed an “overweight” rating and issued a $17.00 price objective on shares of Certara in a research note on Thursday, February 27th. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Certara presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.83.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.